Clinical trial

An Expanded Access Protocol for Setmelanotide for Treatment of Bardet-Biedl Syndrome (BBS)

NCT05183802

StatusAPPROVED_FOR_MARKETING

Study typeEXPANDED_ACCESS

Start dateUnknown

PhaseN/A

Study timeline

Registry last updated2022-08-10

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Bardet-Biedl Syndrome (BBS)unresolved

Obesityunresolved

Interventions

Setmelanotide, administered subcutaneously [SC], once daily.DRUG

Sponsors & collaborators

Rhythm Pharmaceuticals, Inc.lead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05183802 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.